Related Experiment Videos
Bioactive glycyrrhizic acid-astragalus polysaccharide hydrogel facilitates gastric ulcer healing via ROS scavenging
Haocheng Zheng1, Shan Gao2, Yunze Liu3
1Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing 102488, China; School of Traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing 102488, China.
Abstract:
Gastric ulcers are refractory wounds that pose a significant clinical challenge, underscoring the urgent need for effective and affordable therapeutic strategies. In this study, we purified a novel homogeneous astragalus polysaccharide (APS13) and elucidated its structure, which consists of a →4)-α-1,4-Glc(1→ backbone with glucose branches at the 6-position, as determined by 2D-NMR and glycosyl residue analysis. To enhance its tissue adhesion and drug release profile, APS13 was co-assembled with glycyrrhizic acid (GA) into a GA-APS hydrogel. The resulting hydrogel exhibited strong adhesion and prolonged gastric retention under acidic conditions. In vivo and in vitro studies demonstrated that the GA-APS hydrogel reduced ulcer area, improved mucosal integrity, and decreased apoptosis-related protein expression in a rat model of acute gastric ulcer. Comparative analyses showed enhanced therapeutic outcomes relative to treatment with GA or APS13 alone. Proteomic and cellular experiments further indicated that the hydrogel's protective effect is associated with attenuation of ROS-induced apoptosis. These findings highlight the therapeutic potential of APS13-based hydrogels and offer a natural-material strategy for addressing oxidative stress-related gastric injury.
Related Concept Videos
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
Peptic Ulcer Disease IV: Management
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current medication...
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors